A smartphone app pairing exercise with therapy cut chronic knee pain in a trial
In 216 patients with chronic patellofemoral pain across 10 Korean hospitals, an 8-week digital therapeutic beat education and exercise instruction on pain — by 12.5 mm on a 100 mm scale.
"Digital therapeutic" (DTx) is a term for software intended to treat a condition, not merely track it — and the category has often run ahead of its evidence, deployed on the strength of engagement metrics rather than randomised trials. A study published in the British Journal of Sports Medicine on 3 September puts one such product through a proper test, for a stubborn and common complaint: chronic patellofemoral pain [s1].
The condition and the product
Patellofemoral pain — pain at the front or behind the kneecap, provoked by activity — is a frequent reason people see orthopaedic and sports-medicine clinics, and it often persists. The recommended treatment is exercise, but adherence is hard and pain has a psychological dimension that exercise instruction alone does not address.
The trial tested MORA Cure PFP, an eight-week smartphone programme combining two things: personalised home-based exercise and cognitive–behavioural therapy (CBT), delivered as weekly sessions and daily self-reflective worksheets [s1]. The question was whether that integrated package beat the usual first-line approach.
How it was run
This was a multicentre, parallel-group randomised controlled trial of 216 participants with chronic patellofemoral pain — defined as anterior or retropatellar pain lasting at least three months with activity-related provocation — recruited from orthopaedic outpatient clinics at 10 hospitals in the Republic of Korea [s1]. Participants were randomly assigned either to the DTx group or to a control group that received PFP-related education, one-time exercise instruction, printed materials and self-monitoring exercise diaries [s1]. That control matters: it is not a do-nothing comparison but roughly what many patients are given now.
The primary endpoint was "usual" knee pain at eight weeks, measured on a 0–100 mm visual analogue scale (VAS), with outcomes assessed at baseline, 4, 8 and 12 weeks [s1].
The results
On the primary endpoint, the DTx group did better: a between-group mean difference in usual pain at week 8 of −12.5 mm (95% CI −17.1 to −7.8) favouring the app [s1]. Secondary outcomes at week 8 pointed the same way — worst pain (−10.7 mm, 95% CI −15.9 to −5.4), knee function on the Anterior Knee Pain Scale (+5.2 points, 95% CI 2.7 to 7.7), quality of life on the EQ VAS (+10.7 points, 95% CI 7.1 to 14.4), and pain catastrophising on the PCS (−1.8 points, 95% CI −3.3 to −0.3) [s1].
On safety and engagement, exercise adherence exceeded 80%, and no device-related or intervention-related serious adverse events were reported [s1].
Reading it carefully
A 12.5 mm improvement on a 100 mm scale is a real, statistically clear difference, and the fact that pain, function, quality of life and a psychological measure all moved together strengthens the picture. Adherence above 80% is notable for a home exercise programme, and is plausibly where the CBT component earns its place — supporting the behaviour rather than just prescribing it.
But several limits temper how far to carry this. The trial was unblinded, as behavioural trials generally must be: participants knew whether they had an interactive app or a printed handout, and self-reported pain outcomes are exactly the kind that expectation can inflate. The comparison was against minimal support — one-time instruction and leaflets — not against high-quality supervised physiotherapy, so the trial shows the app beats a low bar, not that it matches or exceeds hands-on care. Follow-up ran to 12 weeks, leaving the durability of the benefit unknown. And this is one product tested in one country's clinics; the result does not transfer automatically to other digital therapeutics, which are not interchangeable.
What the trial does provide is something the DTx field frequently lacks: a randomised, multicentre demonstration that a specific app produced a measurable clinical improvement over usual instruction, with good adherence and no serious harms [s1]. That is a meaningful data point — and, equally, a reminder that each such product needs its own trial rather than borrowing another's.
The trial was prospectively registered on ClinicalTrials.gov (NCT06260865) [s2], with its primary endpoint pre-specified — the kind of procedural detail that matters in a category where positive claims have often rested on less rigorous evaluations.
Sources
- Digital therapeutic combining exercise and cognitive–behavioural therapy reduces pain in patients with chronic patellofemoral pain: a multicentre randomised controlled trial — British Journal of Sports Medicine, 2026-09-03
- Digital Therapeutics for Patellofemoral Pain (NCT06260865) — ClinicalTrials.gov
Sources
- Digital therapeutic combining exercise and cognitive–behavioural therapy reduces pain in patients with chronic patellofemoral pain: a multicentre randomised controlled trial — British Journal of Sports Medicine , September 3, 2026
- Digital Therapeutics for Patellofemoral Pain (NCT06260865) — ClinicalTrials.gov
Four Latin American countries digitised their health systems. Tech was the easy part.
Thirty-two interviews across Uruguay, Argentina, Chile and Mexico find implementation turned on governance, not software. A separate patent analysis shows where digital therapeutics are not being built.
An app that nudged long COVID patients to pace themselves did not reduce crashes
A 250-person randomised trial paired a wearable tracker with just-in-time energy-management messages. Post-exertional malaise fell in both arms, and the difference between them was trivial.
A prescribed app cut incontinence episodes 61%. The control group changed by 1.7%.
Germany's DINKS trial is one of the largest randomised tests of a reimbursable digital therapeutic. The effect is big, the comparator is usual care alone, and the sponsor made the app.
An app matched human coaches in a diabetes trial. Both worked about a third of the time.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.